MC
ABCL icon

Maverick Capital’s AbCellera Biologics ABCL Stock Holding History

Maverick Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-48,052
Closed -$310K – 302
2023
Q2 		$310K Sell
48,052
-12,639
-21% -$86.3K 0.01% 344
2023
Q1 		$458K Buy
60,691
+33,054
+120% +$300K 0.01% 297
2022
Q4 		$280K Buy
27,637
+5,184
+23% +$59.9K 0.01% 305
2022
Q3 		$222K Buy
+22,453
New +$246K 0.01% 303

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Maverick Capital's ABCL Position: Q3 2023 in Review

Maverick Capital sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 48,052 shares — an estimated $310K sold.

Maverick Capital first reported a position in ABCL in Q3 2022 and held it in 4 quarters. The position peaked at $458K in Q1 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Maverick Capital reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Maverick Capital sold 48,052 AbCellera Biologics shares in Q3 2023, an estimated $310K.
  • Maverick Capital first reported a position in AbCellera Biologics in Q3 2022 and held it in 4 quarters.
  • Maverick Capital's AbCellera Biologics position peaked at $458K in Q1 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Maverick Capital's 13F filing for Q3 2023, filed 14 Nov 2023.